Article Text

Download PDFPDF
Prenatal and postnatal administration of Lactobacillus GG reduced the occurrence of atopic disease in offspring

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

 QUESTION: In offspring at risk for atopic disease, does oral administration of Lactobacillus GG (LGG), given prenatally to mothers and postnatally to their infants, prevent atopic eczema?


Randomised (unclear allocation concealment*), blinded (clinicians, patients, and outcome assessors),*) controlled trial with 2 years of follow up.


Antenatal clinics in Turku, Finland.


159 pregnant women who had atopic disease, or ≥ 1 first-degree relative (mother, father, or older sibling), or partner with atopic eczema, allergic rhinitis, or asthma. 132 women (83%) and 132 children completed follow up.


Mothers were allocated to LGG (1 × 1010 colony-forming units [Valio Limited, Helsinki, Finland]) (n=77) or to placebo (microcrystalline cellulose) (n=82). The capsules were taken daily for 2 to 4 weeks before expected delivery. After delivery, …

View Full Text


  • Sources of funding: Finnish Foundation for Paediatric Research; National Technology Agency of Finland; Allergy Research Foundation in southwest Finland.

  • For correspondence: Dr M Kalliomäki, Department of Paediatrics, Turku University Hospital, P.O. Box 52, FI-20521 Turku, Finland.

  • * See glossary.